Condition
Melanoma Recurrent
Total Trials
5
Recruiting
0
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Active Not Recruiting3
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04478279Phase 1Active Not Recruiting
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT07376317Phase 2Active Not Recruiting
Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)
NCT06784648Phase 1Active Not Recruiting
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
NCT03311542Unknown
Expanded Access for Pembrolizumab (MK-3475)
NCT02574533Phase 1CompletedPrimary
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
Showing all 5 trials